2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
46
Lung Neoplasms
19
Melanoma
18
Neoplasm Metastasis
16
Carcinoma, Hepatocellular
15
Neoplasms
13
Esophageal Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Colorectal Neoplasms
9
Breast Neoplasms
9
Head and Neck Neoplasms
8
Stomach Neoplasms
6
Rectal Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Carcinoma, Renal Cell
6
Brain Neoplasms
6
Small Cell Lung Carcinoma
5
Recurrence
5
Pancreatic Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Liver Neoplasms
4
Glioblastoma
4
Cholangiocarcinoma
4
Prostatic Neoplasms
3
Nasopharyngeal Carcinoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Interventions
Bevacizumab
3
pralsetinib
2
pembrolizumab
2
osimertinib
2
contrast agent BR1
2
Pemetrexed
2
Oncolytic Virotherapy
2
Carboplatin
2
vorasidenib
1
lutetium Lu 177 dotatate
1
keyhole-limpet hemocyanin
1
interferon gamma-1b
1
copper dotatate CU-64
1
Vaccines
1
Temozolomide
1
Sunitinib
1
Stem Cell Transplantation
1
Paclitaxel
1
Microbubbles
1
Lutetium-177
1
Lutetium
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Gemcitabine
1
Cisplatin
1
Biopsy
1
Antibodies, Monoclonal
1
AZD 6244
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Nerve Tissue
×
Immunotherapy
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled